Medicare Price Negotiation: Special Treatment For ‘Novel Technologies’ On PhRMA’s Advocacy Agenda

Novartis CEO Vasant Narasimhan, PhRMA's incoming board chair, says in an interview that the brand drug association has a slate of issues to pursue as it works to shape the implementation of the Medicare price negotiation program in the name of preserving innovation.

'9/13' Issue Is Highest IRA Priority For Industry • Source: Shutterstock

Medicare should allow for limits on the discounts required for innovative drugs subject to price negotiation as it develops the rules around implementing the program, Novartis Chairman and CEO Vasant Narasimhan said in an interview with the Pink Sheet.

“Are there any protections that [the Centers for Medicare and Medicaid Services] would consider for novel technologies, novel drugs …...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet